List of Excipients in Branded Drug DILAUDID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rhodes Pharmaceuticals LP	DILAUDID	hydromorphone hydrochloride	42858-122	ANHYDROUS LACTOSE
Rhodes Pharmaceuticals LP	DILAUDID	hydromorphone hydrochloride	42858-122	D&C RED NO. 30
Rhodes Pharmaceuticals LP	DILAUDID	hydromorphone hydrochloride	42858-122	D&C YELLOW NO. 10
Rhodes Pharmaceuticals LP	DILAUDID	hydromorphone hydrochloride	42858-122	MAGNESIUM STEARATE
Rhodes Pharmaceuticals LP	DILAUDID	hydromorphone hydrochloride	42858-122	SODIUM METABISULFITE
Purdue Pharma LP	DILAUDID	hydromorphone hydrochloride	59011-441	CITRIC ACID MONOHYDRATE

Generic Drugs Containing DILAUDID

Company	Ingredient	NDC	Excipient
V1 Pharma Llc	hydromorphone hydrochloride	70399-102	ANHYDROUS LACTOSE
V1 Pharma Llc	hydromorphone hydrochloride	70399-102	CELLULOSE, MICROCRYSTALLINE
V1 Pharma Llc	hydromorphone hydrochloride	70399-102	MAGNESIUM STEARATE
V1 Pharma Llc	hydromorphone hydrochloride	70399-102	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in DILAUDID?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	MAGNESIUM STEARATE
1	SILICON DIOXIDE

Last updated: August 15, 2026

Dilaudid is an established hydromorphone brand with limited classic patent protection and substantial generic competition. The strongest commercial opportunities are in excipient-enabled products that improve injection safety, reduce medication errors, support preservative-free use, improve oral tolerability, or create differentiated abuse-deterrent and ready-to-administer presentations. Excipient changes alone do not create a new product opportunity unless they support a clinically meaningful formulation, regulatory advantage, or manufacturing benefit.

Dilaudid Excipient Strategy and Commercial Opportunities for Hydromorphone

What is Dilaudid and how is hydromorphone formulated?

Dilaudid is the brand name for hydromorphone hydrochloride, a potent opioid analgesic used for severe pain. FDA-approved dosage forms include tablets, oral solution, and injectable products. Hydromorphone is a Schedule II controlled substance in the United States.[1]

The commercial formulation landscape includes:

Product type	Active ingredient	Typical strengths	Primary excipient strategy
Immediate-release tablets	Hydromorphone HCl	2 mg, 4 mg, 8 mg	Solid-dose manufacturability, taste masking, tablet robustness
Oral solution	Hydromorphone HCl	Commonly 1 mg/mL	Solubility, preservation, palatability, dose accuracy
Injection	Hydromorphone HCl	Commonly 1 mg/mL, 2 mg/mL, 4 mg/mL	Sterility, pH control, isotonicity, container compatibility
High-potency injection	Hydromorphone HCl	10 mg/mL in selected products	Low-volume administration, concentration control, safety labeling
Generic equivalents	Hydromorphone HCl	Multiple strengths	Cost-efficient excipients and scalable manufacturing

The reference products are mature. Their core composition is generally accessible through FDA labeling, approved product information, and generic drug filings. The principal opportunity is therefore not ownership of the basic hydromorphone molecule. It is the development of differentiated delivery systems and excipient combinations that solve practical problems in hospitals, pharmacies, long-term-care settings, and home care.

What excipients are used in Dilaudid products?

Which excipients are used in hydromorphone tablets?

Hydromorphone tablets typically use standard immediate-release excipients, including combinations of diluents, binders, disintegrants, lubricants, glidants, and coating materials. Product-specific inactive ingredients vary by manufacturer and strength.

Relevant excipient functions include:

• Lactose or microcrystalline cellulose as a filler.
• Povidone or related polymers as a binder.
• Sodium starch glycolate or crospovidone as a disintegrant.
• Magnesium stearate as a lubricant.
• Colloidal silicon dioxide as a flow aid.
• Talc, hypromellose, titanium dioxide, and colorants in film coatings.
• Sucrose or other sweeteners in certain tablet compositions.

FDA-approved hydromorphone tablets are not generally modified-release products. The formulation target is rapid disintegration and dissolution, consistent with immediate-release opioid dosing.[1,2]

Commercially relevant excipient issues include lactose intolerance, colorant sensitivity, tablet friability, powder flow, content uniformity at low dose, and manufacturing controls for potent active pharmaceutical ingredients.

Which excipients are used in Dilaudid oral solution?

Hydromorphone oral solutions require excipients that maintain chemical stability, microbial control, dose uniformity, and acceptable taste. Common functional categories include:

• Purified water or water for pharmaceutical use.
• Buffer components such as citric acid and sodium citrate.
• Preservatives such as methylparaben or propylparaben.
• Sweeteners such as sucrose or sorbitol.
• Humectants and cosolvents such as glycerin or propylene glycol.
• Flavoring agents.
• pH-adjusting agents.

The key development problem is not simply dissolving hydromorphone. It is achieving a stable, palatable, accurately dosed liquid while controlling preservative exposure and minimizing excipient burden in vulnerable patients.

Potential differentiation includes preservative-free oral solution, sugar-free formulations, alcohol-free formulations, low-volume concentrated solution, unit-dose cups, oral syringes, and tamper-evident packaging.

Which excipients are used in Dilaudid injection?

Hydromorphone injection products commonly use a sterile aqueous vehicle with pH and tonicity control. Label-listed excipients can include sodium chloride, citric acid, sodium citrate, and Water for Injection, depending on the specific product.[3]

Injection excipients must support:

• Chemical stability of hydromorphone hydrochloride.
• Acceptable pH and osmolality.
• Sterility and endotoxin control.
• Low particulate burden.
• Compatibility with glass and polymer containers.
• Compatibility with intravenous, intramuscular, and subcutaneous administration.
• Protection from precipitation after dilution.

The Dilaudid-HP presentation has a substantially higher hydromorphone concentration than conventional injection strengths. That reduces administration volume but increases the risk of selection and dosing errors. The commercial value of a high-concentration product depends on strict differentiation, packaging controls, barcode integration, and institutional protocols.[3]

What excipient strategy is most attractive for Dilaudid products?

The strongest strategy is to connect excipient selection with a defined clinical or operational problem.

Preservative-free injectable formulation

A preservative-free hydromorphone injection can target hospitals, intensive-care units, operating rooms, and patients with sensitivity to antimicrobial preservatives. The product must demonstrate sterility assurance, container-closure integrity, stability, and compatibility with the intended administration route.

Commercial advantages include use in sensitive patient populations and simplified institutional formulary policies. The challenge is that many injectable hydromorphone products already use relatively simple aqueous compositions. A new preservative-free product would need a clear benefit in packaging, stability, concentration, or administration workflow.

Ready-to-administer and premixed presentations

Ready-to-administer syringes, cartridges, or small-volume bags can reduce compounding steps and medication-error risk. Relevant excipient and container considerations include:

• Low-sorption syringe materials.
• Extractables and leachables.
• Stability during refrigerated and room-temperature storage.
• Compatibility with automated dispensing systems.
• Low dead volume.
• Barcode readability.
• Protection against accidental concentration interchange.

A ready-to-administer hydromorphone product could compete on labor savings and safety rather than active-ingredient differentiation. Hospital purchasing decisions would likely depend on total cost per administered dose, not merely price per vial.

Low-volume concentrated injection

High-concentration hydromorphone products reduce fluid volume, which can be useful for patients requiring fluid restriction or continuous infusion. The excipient system should support high drug concentration without precipitation, excessive viscosity, or unacceptable local tolerability.

The main commercial barrier is medication safety. Concentrated opioids require distinctive labeling, restricted distribution controls, and strong differentiation from lower-strength products. A formulation that lowers administration volume but increases selection risk may face hospital resistance unless packaging and workflow controls are strong.

Sugar-free and alcohol-free oral solution

A sugar-free oral solution can target diabetes management, dental-risk concerns, and chronic-care settings. An alcohol-free product may improve suitability for pediatric, geriatric, religious, and substance-use-sensitive populations.

Possible excipient systems include:

• Sorbitol or sucralose for sweetness.
• Glycerin for mouthfeel.
• Citric acid and citrate buffers.
• Paraben-free or alternative preservation systems.
• Natural or synthetic flavor systems with low bitterness.

Hydromorphone has a narrow therapeutic index and high potency. Accurate dosing is critical. An oral syringe, unit-dose packaging, and a calibrated adapter may provide greater commercial value than flavor changes alone.

Taste-masked tablets and multiparticulates

Taste masking has limited value for conventional tablets that are swallowed intact. It becomes more important for orally disintegrating tablets, orally dissolving films, sprinkle capsules, and multiparticulate systems.

Potential technologies include:

• Ion-exchange resins.
• Polymer coating of drug particles.
• Lipid-based taste barriers.
• Complexation with cyclodextrins.
• Drug-loaded microparticles.
• Fast-dissolving films with bitterness suppressants.

These products would require evidence that the formulation does not alter hydromorphone exposure, dose uniformity, or abuse potential. Because hydromorphone is highly potent, any dosage form that improves ease of administration must be assessed carefully for accidental ingestion and misuse.

What formulations are protected by patents?

The original hydromorphone molecule and conventional Dilaudid dosage forms are mature technologies. Basic immediate-release tablets, conventional oral solutions, and simple aqueous injections are unlikely to provide meaningful new-molecule patent protection.

Potentially protectable subject matter includes:

• Specific excipient ratios.
• Narrow pH and concentration ranges.
• Stabilized high-concentration injections.
• Preservative-free compositions with defined shelf life.
• Low-sorption container and closure systems.
• Ready-to-administer syringe configurations.
• Abuse-deterrent matrices or coatings.
• Multiparticulate or film dosage forms.
• Formulations that reduce degradation products.
• Manufacturing processes that improve content uniformity or sterility assurance.
• Specific combinations of formulation and administration device.

A formulation patent is stronger when the excipient combination produces an unexpected technical result, such as materially improved stability, reduced degradation, lower injection-site irritation, or a reproducible dissolution profile. A patent that merely substitutes one conventional filler, buffer, sweetener, or preservative for another is more vulnerable to obviousness and routine-optimization challenges.

When does Dilaudid lose exclusivity?

Dilaudid has already lost practical market exclusivity for its conventional hydromorphone presentations. FDA-approved generic hydromorphone tablets, oral solutions, and injections are available from multiple manufacturers.[2,4]

The relevant exclusivity timeline is:

Exclusivity category	Status
Active-ingredient exclusivity	Expired
Conventional product patent exclusivity	Expired or no longer commercially decisive
Generic approval pathway	ANDA pathway available
Controlled-substance status	Schedule II restrictions remain
Biosimilar exclusivity	Not applicable
New formulation exclusivity	Possible only for a separately approved product with qualifying innovation

A new hydromorphone formulation could potentially obtain three-year FDA exclusivity for a new clinical investigation supporting approval of a changed dosage form or formulation, but this would depend on the regulatory pathway and the nature of the approval.[5] Five-year new chemical entity exclusivity is not available for hydromorphone as an old active ingredient.

What is the Orange Book status of Dilaudid?

The Orange Book identifies approved drug products, therapeutic equivalence evaluations, patent information, and exclusivity data. Conventional Dilaudid products are subject to the generic-drug framework, and hydromorphone products have been approved through both reference-product and abbreviated pathways.[4]

For commercial diligence, the relevant points are:

1. Conventional hydromorphone products are generally substitutable with therapeutically equivalent generics where an AB rating applies.
2. Orange Book patent listings should be reviewed product by product because formulations, strengths, manufacturers, and reference products can differ.
3. A new formulation may have a separate NDA and a distinct Orange Book profile.
4. A device or packaging innovation may not qualify for Orange Book listing unless it claims an approved drug product in a manner recognized by FDA regulations.
5. Patent expiry does not eliminate controlled-substance distribution, manufacturing, recordkeeping, or security obligations.

Are there Paragraph IV challenges to Dilaudid?

Paragraph IV litigation is unlikely to be commercially central for the original Dilaudid formulations because generic hydromorphone products are already established. Paragraph IV risk becomes more relevant if a company launches a new branded formulation with unexpired formulation or method-of-use patents.

For a differentiated hydromorphone product, likely challenge targets would include:

• Narrow formulation claims.
• Buffer and pH limitations.
• High-concentration injectable compositions.
• Sustained-release or abuse-deterrent dosage forms.
• Device-related claims tied to administration.
• Stability claims based on routine excipient selection.

A branded formulation sponsor should expect ANDA applicants to test whether the formulation claims are enabled across their full scope and whether the claimed excipient combination produces an unexpected result. Settlement terms involving generic entry dates, authorized generics, licenses, or restrictions would require case-specific review of the relevant patents and court docket.

What is the biosimilar risk for Dilaudid?

There is no biosimilar risk because Dilaudid is a small-molecule drug, not a biologic. The relevant competitors are ANDA-based generic hydromorphone products, 505(b)(2) products, hospital-compounded preparations, and alternative opioid analgesics.

A 505(b)(2) strategy could be more relevant than a conventional ANDA where the sponsor develops:

• A new route of administration.
• A sustained-release product.
• A novel abuse-deterrent formulation.
• A new concentration or delivery device.
• A clinically supported formulation change.
• A product with a different preservative or excipient profile.

Which companies are challenging Dilaudid commercially?

Generic competition comes from multiple manufacturers and labelers, including major generic pharmaceutical companies and specialty injectable suppliers. The competitive field can change as manufacturers enter or exit the market, experience shortages, or alter product portfolios.

The most relevant competitive categories are:

Competitor class	Commercial threat
Generic hydromorphone tablets	High price pressure and therapeutic substitution
Generic injectable hydromorphone	Hospital contracting and supply reliability
Generic oral solution	Pharmacy and long-term-care substitution
Other injectable opioids	Substitution based on supply, protocol, and price
Fentanyl and morphine products	Clinical alternatives in institutional care
Buprenorphine and other analgesic products	Selected pain-management substitution
Compounded preparations	Limited but relevant in shortage or special-use settings

A differentiated product must compete against the lowest-cost generic while proving a measurable advantage in workflow, safety, supply continuity, or patient administration.

What patent litigation affects Dilaudid?

No broad patent-litigation thesis is apparent for conventional Dilaudid products because the core product is old and genericized. Litigation risk is more likely to arise around a new formulation, abuse-deterrent technology, delivery device, or manufacturing process.

Potential disputes could involve:

• Formulation patent infringement.
• Invalidity based on obviousness or lack of written description.
• FDA approval under section 505(b)(2).
• ANDA Paragraph IV certifications.
• Trade-secret claims involving manufacturing.
• Contract disputes involving supply or licensing.
• Regulatory exclusivity for a new dosage form.

The absence of a dominant legacy patent estate can improve market entry prospects but reduces the ability to defend premium pricing.

What licensing deals could support a Dilaudid formulation?

Licensing opportunities are more likely to involve technology platforms than the Dilaudid brand itself. Relevant targets include:

• Abuse-deterrent coating technologies.
• Long-acting injectable delivery systems.
• Ready-to-use syringe platforms.
• Low-sorption polymer containers.
• Taste-masking systems.
• Oral-film technologies.
• Preservative-free multidose packaging.
• Automated compounding and dose-verification systems.

A licensing deal should be evaluated against four commercial constraints: opioid regulatory controls, limited molecule-level differentiation, generic price competition, and the cost of clinical or human-factors studies. Platform rights are most valuable when the technology can also be applied to other controlled substances or hospital injectables.

How strong is the Dilaudid patent estate?

The legacy Dilaudid patent estate is weak as a barrier to conventional generic entry. The product's commercial value rests on brand recognition, historical prescribing, distribution, and manufacturing or supply relationships rather than exclusivity.

A new excipient-based estate can be stronger if it contains:

• Composition claims with narrow but commercially relevant scope.
• Independent claims covering a specific device-container combination.
• Stability data that supports a longer shelf life.
• Claims tied to a clinically meaningful dosing advantage.
• Manufacturing claims that are difficult to design around.
• Multiple continuation applications covering formulation, use, and packaging.

The strongest portfolio would combine composition, process, container, and administration claims. Purely functional claims, such as "a stable hydromorphone formulation," are more exposed unless supported by precise structural limitations and robust comparative data.

What generic launch risks exist for a new hydromorphone formulation?

Generic launch risk depends on the regulatory classification of the product.

ANDA risk

An ANDA applicant may seek approval for a therapeutically equivalent version if the product has the same active ingredient, dosage form, strength, route, and relevant performance characteristics. This is the principal threat to conventional tablets, oral solutions, and injections.

505(b)(2) risk

A 505(b)(2) product can face competition from both ANDA products and other 505(b)(2) applicants. The sponsor may obtain limited exclusivity, but the product must justify its clinical or formulation differentiation.

Manufacturing risk

Hydromorphone is potent, so manufacturing facilities require strong containment, cleaning validation, blend uniformity controls, and diversion prevention. These requirements can raise entry costs, but they are not necessarily durable IP barriers.

Supply risk

Hospital buyers may prioritize uninterrupted supply over formulation novelty. A new product with a unique excipient, container, or sterilization process may experience launch delays if component qualification is difficult.

What are the best commercial opportunities for Dilaudid excipients?

The most credible opportunities rank as follows:

1. Ready-to-administer injectable hydromorphone with robust barcode and packaging controls.
2. Preservative-free injection for sensitive or specialized patient populations.
3. Sugar-free, alcohol-free oral solution with accurate unit-dose delivery.
4. Low-volume concentrated injection with strong error-prevention design.
5. Abuse-deterrent oral formulation supported by meaningful pharmacokinetic and tampering data.
6. Taste-masked pediatric or geriatric dosage form.
7. Container-closure and device systems that improve stability and reduce adsorption.
8. Manufacturing processes that reduce potent-compound handling costs.

The highest-value strategy is likely a hospital-focused injectable product with operational differentiation. Consumer-facing tablet reformulation has lower commercial potential unless it supports a new route, abuse-deterrent profile, or clinically meaningful administration benefit.

Key Takeaways

• Dilaudid contains hydromorphone hydrochloride and is a mature Schedule II opioid product.
• Conventional tablets, oral solutions, and injections face established generic competition.
• The legacy patent estate is unlikely to block conventional generic entry.
• Excipient innovation can create value through stability, preservation, taste masking, abuse deterrence, packaging, and administration safety.
• Ready-to-administer and preservative-free injectable products have the clearest institutional opportunity.
• Sugar-free, alcohol-free, and unit-dose oral solutions offer differentiated pharmacy and long-term-care opportunities.
• Biosimilar risk does not apply; ANDA and 505(b)(2) competition does.
• A defensible new patent estate should combine composition, process, container, and device claims.
• Generic launch risk remains high for products that lack clinically measurable or workflow-based differentiation.
• Commercial success will depend on hospital procurement economics, supply reliability, FDA pathway, and medication-error controls.

FAQs

Can excipients extend Dilaudid patent protection?

Excipients can support new formulation patents, but they do not extend the expired protection for hydromorphone itself. Any new exclusivity would attach to the qualifying formulation or approved product, not to conventional Dilaudid products.

Is hydromorphone oral solution a strong formulation opportunity?

It is a moderate opportunity. Sugar-free, alcohol-free, preservative-free, concentrated, and unit-dose versions may create value, but the formulation must demonstrate stability, accurate dosing, palatability, and a clear commercial advantage over generic solutions.

Can a ready-to-use hydromorphone syringe receive FDA exclusivity?

Potentially. The product would need an appropriate approval pathway and qualifying clinical investigations or formulation innovation. Exclusivity would depend on the specific FDA approval basis and would not necessarily prevent all generic hydromorphone competition.

Which excipients are most important for hydromorphone injection stability?

Buffer components, tonicity agents, the sterile vehicle, and the container-closure system are central. The exact combination must be validated for pH, degradation, precipitation, particulate control, adsorption, and compatibility after dilution.

Does an abuse-deterrent hydromorphone product have strong commercial potential?

It can, but the opportunity is execution-dependent. The sponsor would need meaningful tamper-resistance data, acceptable pharmacokinetics, evidence of abuse-deterrent performance, strong packaging, and a reimbursement or institutional purchasing rationale sufficient to support a premium over generic hydromorphone.

References

1. U.S. Food and Drug Administration. (n.d.). Dilaudid- hydromorphone hydrochloride injection, solution; Dilaudid- hydromorphone hydrochloride tablet; hydromorphone hydrochloride oral solution prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, hydromorphone hydrochloride products. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Dilaudid-HP hydromorphone hydrochloride injection prescribing information. DailyMed.

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, 45th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Food and Drug Administration. (n.d.). New drug product exclusivity. https://www.fda.gov/drugs/development-approval-process-drugs/new-drug-product-exclusivity